MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$115,067K
Free Cash flow
-$89,077K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Maturities of marketable securit...
Proceeds from issuance of pre-fu...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Contract assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-112,452
-98,539
-83,273
119,244
Depreciation and amortization
688
688
721
661
Net accretion of discounts on marketable securities
1,018
1,211
1,524
1,982
Stock-based compensation
16,658
14,536
11,793
12,217
Amortization of right-of-use assets
433
455
476
369
Accounts receivable
-
-
0
-
Prepaid expenses and other assets
1,052
-3,025
5,562
-192
Accounts payable
8,890
3,050
-858
1,191
Accrued and other liabilities
7,793
2,727
-4,799
7,508
Contract assets and liabilities
-
-
5,973
-
Contract liabilities
-
-2,753
-
2,166
Contract assets
9,445
-
-
-
Lease liabilities
707
686
669
648
Net cash used in operating activities
-88,211
-75,170
-90,496
142,214
Purchases of property and equipment, net
866
967
333
42
Purchases of marketable securities
313,433
42,610
236,138
138,991
Maturities of marketable securities
158,367
162,529
138,945
180,800
Net cash (used in) provided by investing activities
-155,932
118,952
-97,526
41,767
Proceeds from issuance of common stock upon public offering, net of issuance costs
183,235
-
0
-
Proceeds from issuance of pre-funded warrants
141,000
-
0
-
Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs
33,202
-9
24,855
-
Proceeds from issuance of common stock, net of issuance costs-At The Market Offering
-
-
-
24,901
Proceeds from exercise of common stock options
851
1,190
1,503
384
Proceeds from espp purchase
922
-
673
0
Net cash provided by financing activities
359,210
1,181
2,130
301
Net increase in cash, cash equivalents and restricted cash
115,067
44,963
-185,892
184,282
Cash, cash equivalents and restricted cash, at beginning of period
158,803
113,840
299,732
85,183
Cash, cash equivalents and restricted cash, at end of period
273,870
158,803
113,840
299,732
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock upon...
$183,235K
Proceeds from issuance of
pre-funded warrants
$141,000K
Proceeds from issuance of
common stock related to...
$33,202K
(32.89%↑ Y/Y)
Proceeds from espp
purchase
$922K
(12.44%↑ Y/Y)
Proceeds from exercise of
common stock options
$851K
(-44.88%↓ Y/Y)
Net cash provided by
financing activities
$359,210K
(1213.48%↑ Y/Y)
Net increase in
cash, cash...
$115,067K
(280.17%↑ Y/Y)
Canceled cashflow
$244,143K
Maturities of marketable
securities
$158,367K
(-56.07%↓ Y/Y)
Stock-based compensation
$16,658K
(-24.64%↓ Y/Y)
Accounts payable
$8,890K
(276.06%↑ Y/Y)
Accrued and other
liabilities
$7,793K
(0.97%↑ Y/Y)
Lease liabilities
$707K
(-42.98%↓ Y/Y)
Depreciation and
amortization
$688K
(-47.80%↓ Y/Y)
Amortization of right-of-use
assets
$433K
(-58.68%↓ Y/Y)
Net cash (used in)
provided by investing...
-$155,932K
(-224.02%↓ Y/Y)
Net cash used in
operating activities
-$88,211K
(28.18%↑ Y/Y)
Canceled cashflow
$158,367K
Canceled cashflow
$35,169K
Purchases of marketable
securities
$313,433K
(34.66%↑ Y/Y)
Net loss
-$112,452K
(24.87%↑ Y/Y)
Purchases of property and
equipment, net
$866K
(-56.55%↓ Y/Y)
Contract assets
$9,445K
Prepaid expenses and
other assets
$1,052K
(-57.41%↓ Y/Y)
Net accretion of
discounts on marketable...
$1,018K
(-84.27%↓ Y/Y)
Buy us a coffee
IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences, Inc. (IDYA)